Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.

THE POWER TO AVOID
HIGHS AND LOWS GUARDIAN™ connect
with guardian™ sensor 3.

For ELIGIBLE CONCESSION CARD HOLDERS

THE POWER OF NDSS FUNDING

New NDSS funding can give eligible people, who previously couldn’t afford CGM, the power to change their lives.

FROM 1 MARCH 2020, the following groups of people will be able to
access fully-subsidised CGM devices through the NDSS:
CONCESSION
CARD HOLDERS
OVER 21
Learn More
Concession Card Holders over the age of 21 who are living with type 1 diabetes and who have a clinical need as assessed by their health care professional.
Pregnancy
Learn More
Women living with type 1 diabetes who are actively planning pregnancy, will be eligible for up to 12 months.
Once pregnant they will be eligible during the pregnancy and for up to three months after the birth of the child.
CHILDREN AND
YOUNG PEOPLE
UNDER 21
Learn More
All eligible T1D who are under 21 can access Guardian Connect with Guardian Sensor 3. If they are on a MiniMed pump then the Guardian Link 3 and Guardian Sensor 3. New sensor will be available on NDSS from 1 April, 2019.
Person Laughing

THE POWER TO LIVE IN A HEALTHY
GLUCOSE RANGE

For too long, eligible Concession Card holders have carried the burden and expense of type 1 diabetes alone.

Now, with NDSS funding, you can offer them the CGM that can give them the opportunity to live in a healthy glucose range.

  • The power to act before a low

    Guardian™ Connect is the only CGM system that can alert your patients with T1D to potential highs and lows up to 1 hour before an event.

    These predictive alerts mean that rather than treat a low, your patients can avoid one, well before it can happen.

  • The power to SHARE SMS ALERTS

    Setting SMS alerts or alarms between 10 minutes and 1 hour before a high or low gives your patients plenty of time to act.

    They can also share these SMS alerts with up to five care partners, providing them with important support and giving them reassurance 24/7.

  • “Because I have had lows, I stay high to avoid them. I know it’s bad for you in the long term but not in the short term.”

    Nicholas, 53-year-old Concession Card Holder

    The power to IMPROVE HbA1c

    The ability to practice tighter glycaemic control can result in improved HbA1c.1

    Knowing they will be alerted by SMS well before they might go low can raise their confidence to a new level.

EXPANDED NDSS
FUNDING FOR
PREGNANCY

from March 1, 2019 (criteria applies) †

It’s delivered! Women who are planning a pregnancy, are pregnant, or who are in the post pregnancy period, can get the power to stay in a healthy glucose range with Guardian™ Connect CGM through the NDSS.

Primary glycaemic outcome showing HbA1c levels in pregnant women with TD1 using Medtronic CGM vs. control1

Pregnant women with T1D using CGM demonstrated significant:
*3.5–7.8mmol/L; †>7.8mmol/L; ‡ 3.5 mmol/L.
  • Reduction in HbA1c Levels1

    at 34 weeks gestation vs. control(-0.19%; 95% CI-0.34 to -0.03; p-0.0279)

  • increased time in target blood glucose range1*

    (p=0.0034)

  • less time in hyper- glycaemia1++

    ( p=0.0279)

  • less time in hypo- glycaemia1++

    (3% vs 4%; p=0.10)

FULLY REIMBURSED by the NDSS for eligible patients :

  • Women living with type 1 diabetes who are actively planning pregnancy, will be eligible for up to 12 months.
  • Once pregnant they will be eligible during the pregnancy and for up to three months after the birth of the child.
The CONCEPTT study1 suggested that “National and international clinical guideline recommendations in Type 1 Diabetes in pregnancy should be revised to recommend offering CGM to pregnant women with Type 1 Diabetes using intensive insulin therapy in the first trimester.”
Person Laughing

NDSS FUNDING FOR CHILDREN AND YOUNG PEOPLE UNDER 21

You can now offer children and young people aged under 21 years with conditions very similar to type 1 diabetes who require insulin, NDSS funding to give them the CGM system to help them live in their healthy glucose range.

To be eligible the child or young person must meet the criteria in the following categories:
Category A – for children 10 years or younger
Children 10 years of age and younger who have been diagnosed with one of the chronic conditions listed in this table will be eligible for subsidised access to CGM if they meet ALL of the following criteria: • The child is expected to benefit clinically from the use of CGM; and

• The family/carer has the willingness and capability to use CGM; and

• The family/carer has the commitment to actively participate in a diabetes management plan that incorporates CGM.

NOTE: A child who has been accessing CGM products through the initiative will continue to have subsidised access after they turn 11. They will not need to be re-assessed under Category B.

Category B – for children and young people aged 11 to less than 21 years
Children and young people who have been diagnosed with one of the chronic conditions listed in this table will be eligible for subsidised access to CGM if they meet ALL of the following criteria: • The person is expected to benefit clinically from the use of CGM; and

• The person or family/carer has the willingness and capability to use CGM; and

• The person or family/carer has the commitment to actively participate in a diabetes management plan which incorporates CGM.

AND they meet ONE OR MORE of the following criteria:

• Frequent significant hypoglycaemia—more than one episode a year of significant hypoglycaemia requiring external, third-party assistance; and/or

• Impaired awareness of hypoglycaemia; and/or

• Inability to recognise, or communicate about, symptoms of hypoglycaemia; and/or

• Significant fear of hypoglycaemia for the child/young person or a family member/carer, which is seriously affecting the health and wellbeing of the child or young person or contributing to hyperglycaemia as a reaction to this fear.

How Predictive alerts helps patients avoid highs and lows

GUARDING WITH MORE ACCURACY
AND COMFORT

Introducing Guardian™ Sensor 3, our most accurate and comfortable sensor yet.

Users of guardian™ connect

spent an average of 61.4% of their
Time in Range over a 9mth period.4

Reduction

in frequency of
Retinopathy5 with
increasing TIR

Reduction

in frequency of
Microalbuminuria5
with increasing TIR


  • HIGHS Avoided

  • LOWS Avoided
  • Predictive Alerts
  • No Predictive Alerts

People who used predictive alerts experienced an improvement in excursions avoided.3

CHOOSING A SMART CGM SYSTEM

Before choosing a CGM system, your patients can use the table below to see the difference the power Guardian™ Connect CGM could make to their life.

1. For more information visit www.ndss.com.au/important-changes-to-the-ndss

2. Cohen O. Guardian™ Connect CGM: Why prediction, education and data interpretation are key for sustained better outcomes. Presented at: 11th International Conference on Advanced

Technologies & Treatments for Diabetes; February, 2018; Vienna, Austria.

3. SMS charges apply

4. Liebl A et al. Continuous Glucose Monitoring: evidence and consensus statement for clinical use. J Diabetes Sci Technol 2013;7(2):500–19.

5. Christiansen MP et al. Diabetes Technol Ther. 2017; Aug 19 (8): 446-456\

6. Beck et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2018 Oct;

7. Data on file

8. Dexcom G5 Mobile System User Guide 2017 Accessed January 2019 from https://amsldiabetes.com.au

9. Reference to Libre FGM IFU